Cartesian Therapeutics (RNAC) Invested Capital (2016 - 2025)
Historic Invested Capital for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$35.8 million.
- Cartesian Therapeutics' Invested Capital fell 486648.94% to -$35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.8 million, marking a year-over-year decrease of 486648.94%. This contributed to the annual value of -$6.8 million for FY2024, which is 9834.85% up from last year.
- Cartesian Therapeutics' Invested Capital amounted to -$35.8 million in Q3 2025, which was down 486648.94% from -$2.5 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Invested Capital registered a high of $102.3 million during Q4 2022, and its lowest value of -$411.9 million during Q4 2023.
- Over the past 5 years, Cartesian Therapeutics' median Invested Capital value was -$1.9 million (recorded in 2021), while the average stood at -$7.4 million.
- Per our database at Business Quant, Cartesian Therapeutics' Invested Capital surged by 491051.27% in 2022 and then crashed by 486648.94% in 2025.
- Over the past 5 years, Cartesian Therapeutics' Invested Capital (Quarter) stood at $28.5 million in 2021, then surged by 259.19% to $102.3 million in 2022, then tumbled by 502.6% to -$411.9 million in 2023, then soared by 98.35% to -$6.8 million in 2024, then crashed by 426.96% to -$35.8 million in 2025.
- Its Invested Capital stands at -$35.8 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$21.8 million for Q1 2025.